沃森生物(300142.SZ)：水痘减毒活疫苗临床试验申请获得受理

Core Viewpoint - Watson Bio (300142.SZ) has applied for clinical trials of its varicella live attenuated vaccine and has received the acceptance notice from the National Medical Products Administration [1] Group 1: Company Developments - The company, along with its subsidiaries Yunnan Vaccine Laboratory Co., Ltd., Beijing Watson Innovation Biotechnology Co., Ltd., and Yuxi Watson Biotechnology Co., Ltd., is jointly developing the varicella live attenuated vaccine [1] - The vaccine is made using the varicella-zoster virus (VZV) live attenuated strain inoculated in human diploid cells and is produced through a freeze-drying process [1] Group 2: Product Information - The vaccine aims to stimulate the immune system to produce immunity against the varicella-zoster virus, thereby preventing chickenpox [1]